Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) - Net Assets

Latest as of March 2026: €41.89 Billion EUR ≈ $48.98 Billion USD

Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5) has net assets worth €41.89 Billion EUR (≈ $48.98 Billion USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€89.76 Billion ≈ $104.94 Billion USD) and total liabilities (€47.87 Billion ≈ $55.96 Billion USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Guangzhou Baiyunshan Pharmaceutical Hold tangible net worth ratio to evaluate the tangible quality of the company's equity base.

Key Net Assets Metrics

Metric	Value
Current Net Assets	€41.89 Billion
% of Total Assets	46.67%
Annual Growth Rate	15.62%
5-Year Change	27.95%
10-Year Change	127.05%
Growth Volatility	26.12

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - Net Assets Trend (2013–2025)

This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's net assets have evolved over time, based on quarterly financial data. See GU5 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.

Annual Net Assets for Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (2013–2025)

The table below shows the annual net assets of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited from 2013 to 2025. For live valuation and market cap data, see how much is Guangzhou Baiyunshan Pharmaceutical Hold worth.

Year	Net Assets	Change
2025-12-31	€40.08 Billion ≈ $46.86 Billion	+6.12%
2024-12-31	€37.77 Billion ≈ $44.16 Billion	+2.98%
2023-12-31	€36.68 Billion ≈ $42.88 Billion	+9.04%
2022-12-31	€33.64 Billion ≈ $39.33 Billion	+7.38%
2021-12-31	€31.33 Billion ≈ $36.62 Billion	+11.07%
2020-12-31	€28.21 Billion ≈ $32.97 Billion	+8.53%
2019-12-31	€25.99 Billion ≈ $30.38 Billion	+12.30%
2018-12-31	€23.14 Billion ≈ $27.06 Billion	+20.15%
2017-12-31	€19.26 Billion ≈ $22.52 Billion	+9.12%
2016-12-31	€17.65 Billion ≈ $20.64 Billion	+103.29%
2015-12-31	€8.68 Billion ≈ $10.15 Billion	+9.62%
2014-12-31	€7.92 Billion ≈ $9.26 Billion	+12.81%
2013-12-31	€7.02 Billion ≈ $8.21 Billion	--

Equity Component Analysis

This analysis shows how different components contribute to Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

Retained earnings have grown by 665.5% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2025)

Component	Amount	Percentage
Retained Earnings	€23.38 Billion	61.88%
Other Components	€14.41 Billion	38.12%
Total Equity	€37.79 Billion	100.00%

Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Competitors by Market Cap

The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited ranked by their market capitalization.

Company	Market Cap
Clean Energy Fuels Corp NASDAQ:CLNE	$414.02 Million
Anhui ANLI Artificial Leather SHE:300218	$414.05 Million
National Fertilizers Limited NSE:NFL	$414.14 Million
Plasson Indus TA:PLSN	$414.68 Million
Bandwidth Inc NASDAQ:BAND	$413.87 Million
China Man-Made Fiber Corp TW:1718	$413.80 Million
Myriad Genetics Inc NASDAQ:MYGN	$413.68 Million
Lets Holding Group Co Ltd SHE:002398	$413.68 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's equity between the two most recent reporting periods.

Equity Growth Insights

From 2024 to 2025, total equity changed from 35,904,527,869 to 37,788,048,347, a change of 1,883,520,478 (5.2%).
Net income of 2,983,113,595 contributed positively to equity growth.
Dividend payments of 1,647,590,738 reduced retained earnings.
Other factors increased equity by 547,997,622.

Equity Change Factors (2024 to 2025)

Factor	Impact	Contribution
Net Income	€2.98 Billion	+7.89%
Dividends Paid	€1.65 Billion	-4.36%
Other Changes	€548.00 Million	+1.45%
Total Change	€-	5.25%

Book Value vs Market Value Analysis

This analysis compares Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

Current price-to-book ratio: 0.07x
The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.

Historical Price-to-Book Ratios

Date	Book Value per Share	Market Price	P/B Ratio
2017-12-31	€11.61	€1.61	x
2018-12-31	€13.34	€1.61	x
2019-12-31	€14.88	€1.61	x
2020-12-31	€16.08	€1.61	x
2021-12-31	€17.88	€1.61	x
2022-12-31	€19.72	€1.61	x
2023-12-31	€21.48	€1.61	x
2024-12-31	€22.08	€1.61	x
2025-12-31	€23.24	€1.61	x

Capital Efficiency Dashboard

This dashboard shows how efficiently Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

Current Return on Equity (ROE): 7.89%
The company has moderate efficiency in generating returns from equity.
DuPont Analysis Breakdown:
• Net Profit Margin: 3.84%
• Asset Turnover: 0.92x
• Equity Multiplier: 2.24x
Recent ROE (7.89%) is below the historical average (12.13%), suggesting potential challenges in capital efficiency.

Historical Capital Efficiency Metrics

Year	Return on Equity	Net Profit Margin	Asset Turnover	Equity Multiplier	Economic Value Added
2013	14.35%	5.57%	1.44x	1.79x	€296.87 Million
2014	15.50%	6.35%	1.32x	1.85x	€423.63 Million
2015	15.39%	6.80%	1.21x	1.88x	€455.27 Million
2016	8.69%	7.53%	0.77x	1.49x	€-226.48 Million
2017	10.92%	9.84%	0.74x	1.50x	€174.50 Million
2018	15.87%	8.15%	0.82x	2.37x	€1.27 Billion
2019	13.19%	4.91%	1.14x	2.35x	€770.40 Million
2020	11.15%	4.73%	1.03x	2.29x	€300.76 Million
2021	12.80%	5.39%	1.04x	2.28x	€813.66 Million
2022	12.37%	5.60%	0.95x	2.33x	€760.01 Million
2023	11.61%	5.37%	0.96x	2.25x	€563.75 Million
2024	7.90%	3.78%	0.92x	2.28x	€-754.96 Million
2025	7.89%	3.84%	0.92x	2.24x	€-795.69 Million

Industry Comparison

This section compares Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited's net assets metrics with peer companies in the Medical Distribution industry.

Industry Context

Industry: Medical Distribution
Average net assets among peers: $-665,715,414
Average return on equity (ROE) among peers: -254.80%

Peer Company Comparison

Company	Net Assets	Return on Equity	Debt-to-Equity	Market Cap
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (GU5)	€41.89 Billion	14.35%	1.14x	$413.91 Million
AKSO HEALTH GR. (SPADR)/3 (8HX)	$199.15 Million	-67.78%	0.08x	$1.60 Billion
EDAP TMS S.A (EDA)	$40.90 Million	-50.33%	1.10x	$128.94 Million
CLOUDR GROUP LTD. (H3L)	$-7.16 Billion	0.00%	0.00x	$32.46 Million
Medios AG (ILM1)	$7.81K	-2115.81%	29.02x	$312.19 Million
M1 Kliniken AG (M12)	$139.90 Million	6.37%	0.42x	$300.08 Million
Paragon Care Limited (PXS)	$291.92 Million	2.87%	2.87x	$130.61 Million
Sigma Healthcare Limited (S5YA)	$476.74 Million	-2.59%	1.54x	$19.74 Billion
TELES Informationstechnologien AG (TLIK)	$-9.46 Million	0.00%	0.00x	$1.89 Million
COSMOS HEALTH NEW DL-01 (V67A)	$24.53 Million	-65.96%	1.21x	$13.23 Million

About Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

F:GU5 Germany Medical Distribution

Market Cap

$413.91 Million

€354.04 Million EUR

Market Cap Rank

#13365 Global

#1387 in Germany

Share Price

€1.61

Change (1 day)

-1.23%

52-Week Range

€1.61 - €2.30

All Time High

€2.30